drugset / Trial / NCT00358553

A Crossover Study Assessing the Pharmacokinetics, Pharmacodynamics, and Safety of Recombinant Human Insulin

NCT00358553

Phase 1 Completed Baxter Healthcare Corporation
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, and safety of recombinant human insulin. The study will consist of 2 phases.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic

Indications

No indication recorded.